Literature DB >> 7846740

Saliva versus blood sampling for therapeutic drug monitoring in children: patient and parental preferences and an economic analysis.

R Gorodischer1, P Burtin, P Hwang, M Levine, G Koren.   

Abstract

The objective of this study was to conduct an assessment of patient and parental preferences and an economic analysis of hospital costs in sampling blood and saliva for therapeutic drug monitoring (TDM). Costs and preferences were evaluated in the course of a study, which compared anticonvulsant concentrations in blood routinely drawn for therapeutic monitoring and in saliva in infants and children attending a pediatric neurology clinic. Parents of 84.8% of children, and half of the children, indicated a preference for saliva sampling over venous blood drawing. Children who had been on medications that required therapeutic monitoring for < 2 years were more likely to prefer saliva sampling as compared to those who were under treatment for > or = 2 years. Computation, based upon a basic assumption that a registered nurse obtained blood and a medical technician or a registered nurse assistant sampled saliva, indicated that for every 1,000 cases of changing from blood to saliva sampling, total cost savings would amount to $1,930 for cooperative children and $1,660 for infants and uncooperative children. This saving is equivalent to approximately 100 h of a registered nurse's initial salary. The important contributions to the differential cost were derived from the requirements for more highly trained individuals to take the blood sample and from the doubling time required for the procedure.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7846740     DOI: 10.1097/00007691-199410000-00001

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  18 in total

Review 1.  Pharmacoeconomics: where is the link with pharmacokinetics and biopharmaceutics?

Authors:  F Peys
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Apr-Jun       Impact factor: 2.441

Review 2.  Pharmacoeconomics: where is the link with pharmacokinetics and biopharmaceutics?

Authors:  F Peys
Journal:  Pharm World Sci       Date:  1997-04

Review 3.  Pharmacokinetic studies in infants using minimal-risk study designs.

Authors:  Julie Autmizguine; Daniel K Benjamin; P Brian Smith; Mario Sampson; Philippe Ovetchkine; Michael Cohen-Wolkowiez; Kevin M Watt
Journal:  Curr Clin Pharmacol       Date:  2014

4.  A descriptive systematic review of salivary therapeutic drug monitoring in neonates and infants.

Authors:  Laura Hutchinson; Marlene Sinclair; Bernadette Reid; Kathryn Burnett; Bridgeen Callan
Journal:  Br J Clin Pharmacol       Date:  2018-03-25       Impact factor: 4.335

5.  Clinical validation of the analysis of fluconazole in oral fluid in hospitalized children.

Authors:  Kim C M van der Elst; Manouche van Alst; Marjolijn N Lub-de Hooge; Kai van Hateren; Jos G W Kosterink; Jan-Willem C Alffenaar; Elisabeth H Schölvinck
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

Review 6.  Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants.

Authors:  H Liu; M R Delgado
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

7.  Correlation of paired toxic plasma and saliva paracetamol concentrations following deliberate self-poisoning with paracetamol.

Authors:  Jessamine H Soderstrom; Daniel M Fatovich; Christine Mandelt; Sam Vasikaran; David L McCoubrie; Frank F Daly; Sally A Burrows
Journal:  Br J Clin Pharmacol       Date:  2012-07       Impact factor: 4.335

Review 8.  Alternative matrices for therapeutic drug monitoring of immunosuppressive agents using LC-MS/MS.

Authors:  Mwlod Ghareeb; Fatemeh Akhlaghi
Journal:  Bioanalysis       Date:  2015       Impact factor: 2.681

9.  Investigation of Saliva as an Alternative to Plasma Monitoring of Voriconazole.

Authors:  Kim Vanstraelen; Johan Maertens; Patrick Augustijns; Katrien Lagrou; Henriette de Loor; Raf Mols; Pieter Annaert; Anne Malfroot; Isabel Spriet
Journal:  Clin Pharmacokinet       Date:  2015-11       Impact factor: 6.447

10.  Clinical validation of the analysis of linezolid and clarithromycin in oral fluid of patients with multidrug-resistant tuberculosis.

Authors:  M S Bolhuis; R van Altena; K van Hateren; W C M de Lange; B Greijdanus; D R A Uges; J G W Kosterink; T S van der Werf; J W C Alffenaar
Journal:  Antimicrob Agents Chemother       Date:  2013-05-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.